Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Edge Medical Raises HK$1.2 Billion in Hong Kong IPO to Fund Surgical Robot Pipeline

Fineline Cube Dec 30, 2025
Company Deals

Buchang Pharmaceuticals Signs Exclusive Malaysia Deal for Efparepoetin CKD Anemia Drug

Fineline Cube Dec 30, 2025
Company Deals

Hansoh Pharma Licenses Hengrui’s SHR6508 for RMB 220 Million to Expand Renal Portfolio

Fineline Cube Dec 29, 2025
Company Deals

Luye Pharma Divests 25% Nanjing Luye Stake in RMB 1.1 Billion Complex Option Deal

Fineline Cube Dec 29, 2025
Company Deals

Transcenta Licenses HiCB Platform to EirGenix for Continuous Biomanufacturing

Fineline Cube Dec 29, 2025
Policy / Regulatory

Haihe Biopharma’s Risovalisib Enters China SPARK Project for Pediatric PIK3CA Disorders

Fineline Cube Dec 30, 2025
Company Drug

Hengrui’s HRS-6257 Receives IND Approval for Novel Pain Therapy in China

Fineline Cube Dec 30, 2025
Company Drug

Recbio’s REC610 Shingles Vaccine NDA Accepted by NMPA, Challenging GSK’s Shingrix

Fineline Cube Dec 30, 2025
Company Deals

Zhejiang Dian Diagnostics Partners with Chengdu Eastern New Area for IVD Hub

Fineline Cube Nov 25, 2022

China-based Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244) has announced a strategic partnership with Chengdu...

Company Deals

Anyeep Raises RMB 100 Million in Series A Financing for Mass Spectrometry Development

Fineline Cube Nov 25, 2022

Anyeep, a Suzhou-based developer of mass spectrometers, has reportedly raised close to RMB 100 million...

Company Deals

Shanghai Henlius Biotech to Provide R&D Services for COVID-19 Therapy Azvudine

Fineline Cube Nov 25, 2022

China-based Shanghai Henlius Biotech (HKG: 2696) has entered into an agreement to provide clinical study...

Company Drug

China Resources Double-Crane Gains Approval for Definity in China

Fineline Cube Nov 25, 2022

China Resources Double-Crane Pharmaceutical Co., Ltd (SHA: 600062) has announced receiving market approval from the...

Company Deals

XtalPi Partners with CK Life Sciences to Develop AI Cancer Vaccine Platform

Fineline Cube Nov 25, 2022

Sino-US artificial intelligence (AI) firm XtalPi Inc. has struck a partnership with China-based CK Life...

Company Drug

Bliss Bio’s BB-1709 Accepted for Review by China’s CDE

Fineline Cube Nov 25, 2022

Hangzhou-based oncology-focused clinical stage biotech Bliss Bio has announced that its clinical filing for the...

Company Deals

Xiling Lab Raises RMB 100 Million for ADC Development and IND Filing

Fineline Cube Nov 25, 2022

Xiling Lab, a Chengdu-based drug developer specializing in catalytic synthesis technology, has reportedly raised close...

Company Deals

PrimeLink Bio Raises Funds for ADC Development and R&D Expansion

Fineline Cube Nov 25, 2022

Shenzhen-based drug developer PrimeLink Bio has reportedly raised “hundreds of millions” of renminbi in a...

Company Medical Device

AnchorDx’s UriFind Receives Breakthrough Therapy Designation for Urothelial Carcinoma

Fineline Cube Nov 24, 2022

China-based Guangzhou AnchorDx Medical Co., Ltd, a specialist in methylation high-throughput sequencing, has obtained a...

Company Deals

Visen Pharmaceuticals Files for Hong Kong IPO with Focus on Growth Hormone

Fineline Cube Nov 24, 2022

Visen Pharmaceuticals, a China-based joint venture between Denmark-headquartered Ascendis Pharma and Chinese healthcare-focused investment firm...

Company Drug

Junshi Biosciences Files for UK Approval of PD-1 Inhibitor Tuoyi

Fineline Cube Nov 24, 2022

China-based Junshi Biosciences (HKG: 1877, SHA: 688180) has announced that it has filed for market...

Company

CSPC Pharmaceutical Reports Q3 2022 Financials with 13.8% Revenue Growth

Fineline Cube Nov 24, 2022

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has released its Q3 2022 financial results, reporting...

Company Policy / Regulatory

Tianjin Tianyao Fined for Anti-Monopoly Violations in Carmustine Sales

Fineline Cube Nov 24, 2022

China-based Tianjin Tianyao Pharmaceutical Co., Ltd (SHA: 600488) has been fined RMB 27.72 million (USD...

Policy / Regulatory

China Releases Third Batch of VAT Discounts for Anti-Tumor and Rare Disease Drugs

Fineline Cube Nov 24, 2022

The Ministry of Finance, General Administration of Customs, State Taxation Administration, and National Medical Products...

Company Deals

OrbusNeich Files for IPO on Hong Kong Stock Exchange

Fineline Cube Nov 24, 2022

Vascular intervention specialist OrbusNeich Medical Group Limited, a Wholly Owned Foreign Enterprise (WOFE) based in...

Company Drug

Immorna’s JCXH-221 mRNA Vaccine Cleared by FDA for Phase I/II Study

Fineline Cube Nov 24, 2022

Immorna (Hangzhou) Biotechnology Co., Ltd has announced that the US FDA has cleared its investigational...

Company Deals

Henlius Biotech Partners with Shantou Central Hospital for Clinical Study Collaboration

Fineline Cube Nov 24, 2022

China-based Shanghai Henlius Biotech (HKG: 2696) has announced a strategic clinical study cooperation agreement with...

Company Medical Device

AnchorDx Initiates US Registrational Study for UriFind Urothelial Carcinoma Diagnostic

Fineline Cube Nov 24, 2022

China-based AnchorDx Medical Co., Ltd, a specialist in methylation high-throughput sequencing, has announced the initiation...

Company R&D

Biocytogen Announces Successful Development of Fully-Human Nano Antibody RenNano

Fineline Cube Nov 24, 2022

Biocytogen (Beijing) Co., Ltd has announced the successful research and development of a fully-human nano...

Company Drug

Kanghong Pharma Receives FDA Approval for KH631 Gene Therapy Trial

Fineline Cube Nov 24, 2022

China-based Chengdu Kanghong Pharmaceutical Group Co., Ltd (SHE: 002773) has announced receiving clinical trial approval...

Posts pagination

1 … 532 533 534 … 603

Recent updates

  • Hengrui’s HRS-6257 Receives IND Approval for Novel Pain Therapy in China
  • Recbio’s REC610 Shingles Vaccine NDA Accepted by NMPA, Challenging GSK’s Shingrix
  • Edge Medical Raises HK$1.2 Billion in Hong Kong IPO to Fund Surgical Robot Pipeline
  • J&J’s JNJ-5939 Fails Phase 2b Efficacy Endpoint, Triggers Early Termination of Atopic Dermatitis Trial
  • HutchMed’s Fanregratinib Wins NMPA Priority Review for FGFR2+ Cholangiocarcinoma
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hengrui’s HRS-6257 Receives IND Approval for Novel Pain Therapy in China

Company Drug

Recbio’s REC610 Shingles Vaccine NDA Accepted by NMPA, Challenging GSK’s Shingrix

Company Deals

Edge Medical Raises HK$1.2 Billion in Hong Kong IPO to Fund Surgical Robot Pipeline

Company Drug

J&J’s JNJ-5939 Fails Phase 2b Efficacy Endpoint, Triggers Early Termination of Atopic Dermatitis Trial

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.